EQL PHARMA AB Capital Reinvestment Ratio
EQL PHARMA AB capital reinvestment ratio. EQL PHARMA AB (7JK) has a Capital Reinvestment Ratio of 1.03x as of March 2026, meaning it reinvests 1% of its operating cash flow (€16.79 Million) in capital expenditures (€17.22 Million). See EQL PHARMA AB (7JK) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of EQL PHARMA AB (2022–2026)
Capital reinvestment ratio of EQL PHARMA AB from 2022 to 2026. This chart tracks EQL PHARMA AB's Capital Reinvestment Ratio across 3 annual periods. See 7JK financial flexibility score to measure the company's free cash flow as a share of total liabilities.
EQL PHARMA AB Capital Reinvestment Ratio by Year (2022–2026)
EQL PHARMA AB capital reinvestment ratio by year from 2022 to 2026. For the full cash flow conversion analysis, see 7JK cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2026 | 2.37x | €28.36 Million | €67.24 Million | ▲ +219.2% |
| 2023 | 0.74x | €27.62 Million | €20.51 Million | ▲ +40.6% |
| 2022 | 0.53x | €41.83 Million | €22.09 Million | — |